Search Results - Gendrano, I.N

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons who Inject Drugs Receiving Opioid Agonist Therapy

    C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons who Inject Drugs Receiving Opioid Agonist The... by Arduino, J.M, Shibolet, O, Litwin, A.H, Grebeley, J, Altice, F, Nwankwo, C, Mast, T.C, Jiang, Z, Gendrano, I.N, Platt, H.L, Dore, G.J

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

    C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT) by Dore, G, Altice, F, Litwin, A.H, Grebely, J, Dalgard, O, Gane, E.J, Shibolet, O, Luetkemeyer, A, Nahass, R, Peng, C.-Y, Conway, B, Gendrano, I.N, Huang, H.-C, Chen, E, Nguyen, B.-Y, Wahl, J, Barr, E, Robertson, M, Platt, H.L

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    O33 SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 mg AND 50 mg DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

    O33 SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 mg AND 50 mg DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS by Lagging, M, Brown, A, Weiland, O.R, Mantry, P, Ramji, A, Weilert, F, Vierling, J.M, Talaty, J, Gendrano, I.N, Hwang, P, Zhang, B, Wahl, J, Robertson, M, Mobashery, N

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    803 RELATIONSHIP BETWEEN TRANSAMINASE LEVELS AND PLASMA PHARMACOKINETICS FOLLOWING ADMINISTRATION OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) TO HCV GENOTYPE (G) 1 TREATMENT-NAÏVE PATIENTS

    803 RELATIONSHIP BETWEEN TRANSAMINASE LEVELS AND PLASMA PHARMACOKINETICS FOLLOWING ADMINISTRATION OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) TO HCV GENOTYPE (G... by Caro, L, Du, L, Huang, S, Wenning, L, Su, J, Hwang, P.M.T, Valesky, R, Gilbert, C, Gress, J, Klaassen, F, Gendrano, I.N, Brunhofer, J, Cooreman, M, Huisman, J, Mobashery, N

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    P777 DOSE-DEPENDENT PHARMACOKINETICS FOR MK-5172 25 mg, 50 mg, AND 100 mg ONCE-DAILY FOR 12 WEEKS IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

    P777 DOSE-DEPENDENT PHARMACOKINETICS FOR MK-5172 25 mg, 50 mg, AND 100 mg ONCE-DAILY FOR 12 WEEKS IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS by Caro, L, Talaty, J, Morrison, M, Zhang, S, Guo, Z, Gendrano III, I.N, Hwang, P, Mobashery, N

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    THU-225 - C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons who Inject Drugs Receiving Opioid Agonist Therapy

    THU-225 - C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons who Inject Drugs Receiving Opioid A... by Arduino, J.M., Shibolet, O., Litwin, A.H., Grebeley, J., Altice, F., Nwankwo, C., Mast, T.C., Jiang, Z., Gendrano, I.N., Platt, H.L., Dore, G.J.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    SAT-163 - C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

    SAT-163 - C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT) by Dore, G., Altice, F., Litwin, A.H., Grebely, J., Dalgard, O., Gane, E.J., Shibolet, O., Luetkemeyer, A., Nahass, R., Peng, C.-Y., Conway, B., Gendrano, I.N., Huang, H.-C., Chen, E., Nguyen, B.-Y., Wahl, J., Barr, E., Robertson, M., Platt, H.L.

    Published in Journal of hepatology
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: